BioTuesdays

Category - Markets

Conatus
Markets

Roth cuts Conatus Pharma to neutral with PT of $1.70

Roth Capital Partners downgraded Conatus Pharmaceuticals (NASDAQ:CNAT) to “neutral” with a price target of $1.70 after the company’s ENCORE-NF trial failed to meet its primary endpoint of an improvement of fibrosis...

March 26, 2019
Recro Pharma
Markets

Roth cuts Recro Pharma to neutral with PT $7.50

Roth Capital Partners downgraded Recro Pharma (NASDAQ:REPH) to “neutral” with a price target of $7.50 after the company received a second complete response letter (CRL) from the FDA about its NDA for meloxicam, an...

March 25, 2019
Nevro
Markets

Canaccord ups Nevro PT to $62 from $46

Canaccord Genuity raised its price target for Nevro (NYSE:NVRO) to $62 from $46 after the medical device maker appointed Keith Grossman as president and CEO, effective immediately. The stock closed at $44.77 on March 19...

March 20, 2019
INmune Bio
Markets

Maxim starts INmune Bio at buy; PT $13

Maxim Group launched coverage of INmune Bio (NASDAQ:INMB) with a “buy” rating and $13 price target. The stock closed at $7.73 on March 18. INmune Bio is a clinical-stage immunotherapy company with three drug programs...

March 19, 2019
Momenta Pharma
Markets

BTIG starts Momenta Pharma at neutral

BTIG launched coverage of Momenta Pharmaceuticals (NASDAQ:MNTA) with a “neutral” rating. The stock closed at $14.15 on March 15. Analyst Thomas Schrader writes that Momenta’s transition from a generics company to a more...

March 18, 2019
InMed Pharma
Markets

Roth starts InMed Pharma at buy; PT $1.10

Roth Capital Partners initiated coverage of InMed Pharmaceuticals (TSX:IN; OTCQX:IMLFF) with a “buy” rating and 12-month price target of $1.10. The stock closed at 57 cents on March 15. InMed is focused on developing...

March 18, 2019
Arcus Biosciences
Markets

BTIG starts Arcus Biosciences at buy; PT $20

BTIG initiated coverage of Arcus Biosciences (NYSE:RCUS) with a “buy” rating and $20 price target. The stock closed at $11.67 on March 15. Arcus is focused on driving antitumor immune responses beyond the level...

March 18, 2019
Fluidigm
Markets

BTIG starts Fluidigm at buy; PT $15

BTIG launched coverage of Fluidigm (NASDAQ:FLDM) with a “buy” rating and price target of $15. The stock closed at $12.79 on March 13. Analyst Sung Ji Nam writes that the long-term growth or market potential for the...

March 14, 2019
Vapotherm Logo
Markets

Canaccord ups Vapotherm PT to $27 from $22

Canaccord Genuity raised its price target for Vapotherm (NYSE:VAPO) to $27 from $22 after the company’s fourth quarter results beat expectations. The stock closed at $19.85 on March 12. The company, which develops non...

March 13, 2019